OPK vs. FOLD, LGND, DVAX, BCRX, MNKD, CLDX, NVAX, GERN, INVA, and MYGN
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), Geron (GERN), Innoviva (INVA), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.
OPKO Health vs.
Amicus Therapeutics (NASDAQ:FOLD) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
Amicus Therapeutics received 21 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 72.98% of users gave Amicus Therapeutics an outperform vote while only 65.68% of users gave OPKO Health an outperform vote.
64.6% of OPKO Health shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 47.3% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Amicus Therapeutics presently has a consensus target price of $16.75, suggesting a potential upside of 94.99%. OPKO Health has a consensus target price of $2.75, suggesting a potential upside of 58.05%. Given Amicus Therapeutics' higher possible upside, research analysts plainly believe Amicus Therapeutics is more favorable than OPKO Health.
Amicus Therapeutics has higher earnings, but lower revenue than OPKO Health. Amicus Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.
Amicus Therapeutics has a net margin of -10.62% compared to OPKO Health's net margin of -18.65%. Amicus Therapeutics' return on equity of 12.44% beat OPKO Health's return on equity.
In the previous week, OPKO Health had 1 more articles in the media than Amicus Therapeutics. MarketBeat recorded 7 mentions for OPKO Health and 6 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.06 beat OPKO Health's score of 0.85 indicating that Amicus Therapeutics is being referred to more favorably in the media.
Summary
Amicus Therapeutics beats OPKO Health on 10 of the 18 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
This page (NASDAQ:OPK) was last updated on 3/28/2025 by MarketBeat.com Staff
